HOMEPRODUCTSSERVICESCOMPANYCONTACTFAQResearchDictionaryPharmaMobileSign Up FREE or Login

Greg A Gerhardt Selected Research

Glial Cell Line-Derived Neurotrophic Factor (GDNF)

2/2012Enhanced dopamine transporter activity in middle-aged Gdnf heterozygous mice.
4/2007Unilateral intraputamenal glial cell line-derived neurotrophic factor in patients with Parkinson disease: response to 1 year of treatment and 1 year of withdrawal.
12/2006Point source concentration of GDNF may explain failure of phase II clinical trial.
1/2006Unilateral intraputaminal glial cell line-derived neurotrophic factor in patients with Parkinson disease: response to 1 year each of treatment and withdrawal.
12/2004Caloric restriction increases neurotrophic factor levels and attenuates neurochemical and behavioral deficits in a primate model of Parkinson's disease.
7/2004Striatal GDNF administration increases tyrosine hydroxylase phosphorylation in the rat striatum and substantia nigra.
10/2002Chronic, controlled GDNF infusion promotes structural and functional recovery in advanced parkinsonian monkeys.
1/2002Adeno-associated viral delivery of GDNF promotes recovery of dopaminergic phenotype following a unilateral 6-hydroxydopamine lesion.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research network!


Choose Username:
Email:
Password:
Verify Password:


Research Interface PRO additionally includes drill-down to evidence, articles by author, export to Excel, FDA Link and mobile subscription:
1 year subscription, $490.00 USD

Greg A Gerhardt Research Topics

Disease

11Parkinson Disease (Parkinson's Disease)
02/2012 - 01/2002
3Brain Injuries (Brain Injury)
03/2012 - 05/2010
3Neurodegenerative Diseases (Neurodegenerative Disease)
12/2007 - 10/2002
1Atrophy
03/2012
1Ataxia (Dyssynergia)
03/2012
1Dementia (Dementias)
03/2012
1Hypersensitivity (Allergy)
01/2012
1Postherpetic Neuralgia
07/2011
1Anxiety Disorders (Anxiety Disorder)
07/2011
1Diabetic Neuropathies (Diabetic Neuropathy)
07/2011
1Epilepsy (Aura)
07/2011
1Fibromyalgia (Fibrositis)
07/2011
1Pain (Aches)
07/2011
1Seizures (Seizure)
01/2010
1Ischemia
01/2010
1Dyskinesias (Dyskinesia)
02/2009
1Parkinsonian Disorders (Parkinsonism)
02/2008
1Attention Deficit Disorder with Hyperactivity (Attention Deficit Hyperactivity Disorder)
04/2007
1Hypokinesia (Bradykinesia)
11/2006

Drug/Important Bio-Agent (IBA)

8Glial Cell Line-Derived Neurotrophic Factor (GDNF)IBA
02/2012 - 01/2002
7Dopamine (Intropin)FDA LinkGeneric
03/2012 - 01/2002
4Glutamic Acid (Glutamate)FDA Link
01/2012 - 12/2007
2PotassiumIBA
01/2012 - 05/2010
2Neurotransmitter Agents (Neurotransmitter)IBA
01/2010 - 12/2007
2Levodopa (L Dopa)FDA LinkGeneric
02/2009 - 10/2002
21- Methyl- 4- phenyl- 1,2,3,6- tetrahydropyridine (MPTP)IBA
02/2008 - 11/2006
2Amphetamine (Amfetamine)FDA LinkGeneric
04/2007 - 11/2006
1Tyrosine 3-Monooxygenase (Tyrosine Hydroxylase)IBA
03/2012
1salicylhydroxamic acid (SHAM)IBA
03/2012
1gabapentin (Neurontin)FDA LinkGeneric
07/2011
1pregabalin (Lyrica)FDA Link
07/2011
1Prostaglandins B (PGB)IBA
07/2011
1Potassium ChlorideFDA LinkGeneric
05/2010
1Trichloroethylene (Trichloroethene)IBA
02/2008
1NeurotoxinsIBA
02/2008
1Dextroamphetamine (Dexedrine)FDA LinkGeneric
04/2007
1AdderallIBA
04/2007
1SaltsIBA
04/2007
1ApomorphineIBA
11/2006
1Dopamine Agents (Dopaminergic Agents)IBA
11/2006
1IronIBA
10/2005
1Proteins (Proteins, Gene)IBA
01/2003
1PeptidesIBA
01/2003

Therapy/Procedure

2Microelectrodes
01/2012 - 05/2010
1Caloric Restriction
12/2004